Transformational Quarter Marked by Clinical Validation, Regulatory Progress, and Strategic Momentum in Commercial AI Platform Launch LP-184 Phase 1a clinical trial results demonstrate all primary endpoints achieved with 48% clinical benefit rate in evaluable cancer patients at or above therapeutic dose threshold; marked tumor reductions observed in patients with DNA damage repair mutations including CHK2, ATM, and... Read More

Webcast to be held Thursday, November 13th, 9:00 a.m. ET, register for the webcast here , or at the link provided below. DALLAS / Nov 06, 2025 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR ® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that... Read More

Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, will both be available as open-access services for Lantern's partners and collaborators and are both being advanced as part of a broader multi-agentic initiative at Lantern Pharma. DALLAS / Oct 30, 2025 / Business Wire / Lantern... Read More

AI-advanced drug candidate achieves complete metabolic response after two cycles in patient who failed CAR-T and bispecific antibody therapies, validating LP-284’s mechanism of action. A novel differentiated synthetic lethal mechanism targeting DNA repair deficiencies via transcription-coupled nucleotide excision repair (TC-NER), enabling activity regardless of TP53 mutation status or surface antigen expression while... Read More

DALLAS / Oct 24, 2025 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern management will be presenting at the ThinkEquity Conference on Thursday, October 30, 2025, at 11:30 a.m. ET at the Mandarin Oriental in New York, NY.... Read More

LP-184 achieves all primary endpoints and demonstrates a favorable safety and tolerability profile positioning it for both monotherapy or synergistic combinations with PARP inhibitors and immunotherapies. Clinical benefit observed in 48% of evaluable cancer patients at or above the therapeutic dose threshold. Durable clinical benefits were observed in hard-to-treat tumors like glioblastoma multiforme (GBM), gastrointestinal... Read More

DALLAS / Sep 03, 2025 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven clinical -stage oncology company developing targeted therapies for cancer that are being advanced using its proprietary computational biology and machine learning platform, today announced the successful completion of a Type C meeting with the U.S. Food and Drug Administration (FDA). The meeting provided critical guidance on the... Read More

Major milestone achieved with successful completion of enrollment for LP-184 Phase 1a clinical trial, with 65 patients enrolled across a range of solid tumors including glioblastoma (GBM); LP-184 is a potential blockbuster drug-candidate with market potential of $10-12 billion USD in annual revenue. Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) established for LP-184, enabling advancement to upcoming Phase... Read More

Novel combination therapy with STAR-001 targets the most aggressive and deadliest forms of brain cancer at first progression GBM represents an annual market opportunity of $3 to $5 billion USD with an accelerating number of cases globally Lantern Pharma has previously received both FDA Orphan and Fast Track Designations in GBM DALLAS / Aug 06, 2025 / Business Wire / Starlight Therapeutics , a wholly owned subsidiary of... Read More

Industry-Leading Platform Achieves 94% Accuracy with Real-Time Machine Learning, Providing Open-Access to Critical CNS Drug Development Technology Additional Predictive, Analytic and Descriptive Modules are Planned for Release Leveraging Lantern’s Large-Scale Molecular Features Data Lake and Proprietary Ensemble Algorithmic Approach DALLAS / Aug 04, 2025 / Business Wire / Lantern Pharma Inc . (NASDAQ: LTRN), a pioneering... Read More

Japanese patient cohort enrollment is completed ahead of schedule at multiple clinical sites including the National Cancer Center in Tokyo The incidence rate of never-smokers with non-small cell lung cancer (NSCLC) in Japan is 35 to 40%, double that of the rates in US and European populations The treatment of never-smoker with NSCLC represents a market opportunity estimated at over $4 billion annually There are no approved... Read More

Seasoned Biotech Executive & Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development DALLAS / Jul 28, 2025 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today... Read More

AI-guided, synthetic lethal therapy achieves complete metabolic response after just two cycles in patient who failed three prior state-of-the-art treatment regimens. Complete response in an aggressive, recurring B-cell cancer underscores how AI development can accelerate meaningful patient outcomes in global oncology therapeutic markets where billions are spent on therapies. DALLAS / Jul 23, 2025 / Business Wire / Lantern... Read More

The EU patent allowance strengthens the prior patent allowance for LP-284 in the US, Japan India and Mexico. LP-284 has the potential to address B-cell lymphomas and other B-cell driven malignancies addressing a $4+ billion annual market need LP-284 is in an active Phase 1 trial in the US focused on lymphomas and other B-cell cancers with a potential completion in late 2025 DALLAS / Jul 21, 2025 / Business Wire / Lantern... Read More

The AI module, trained on 221 clinical trials, will be incorporated as part of Lantern’s AI platform, RADR ® , and will initially focus on tailored combinations of DNA damaging agents and DNA repair inhibitors Addresses $50+ billion combination cancer therapy market projected to grow 8.5% annually through 2030 Over 60% of cancer patients received DNA damaging agents or DNA repair inhibitors as part of their clinical... Read More

DALLAS / Jun 16, 2025 / Business Wire / Lantern Pharma Inc . (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR ® AI platform, today announces remarkable clinical observations for a patient in Lantern’s Phase 2 HARMONIC™ clinical trial. A 70-year-old never-smoker with advanced non-small cell lung cancer (NSCLC) has achieved a durable complete response in... Read More

Independent research from Johns Hopkins validates Lantern's data used to secure the FDA Rare Pediatric Disease Designation for LP-184 in ATRT and supports planned pediatric clinical trial DALLAS / May 29, 2025 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging advanced AI and machine learning to transform the cost, pace, and timeline of oncology drug development, today... Read More

Completion of LP-184 Phase 1a clinical trial enrollment with 62-65 patients across a range of solid tumors expected by end of June 2025. Additional patient data readout from the HARMONIC™ Trial evaluating LP-300 in never-smokers with non-small cell lung cancer (NSCLC) anticipated in Q3 2025, including initial readout for patients from the Asian expansion cohort. Strengthened AI intellectual property portfolio with PCT... Read More

Drug candidate LP-184 to be evaluated in combination with immune checkpoint inhibitors in biomarker-defined NSCLC patients with KEAP1 and/or STK11 mutations and low PD-L1 expression. The FDA has cleared the LP-184 investigational new drug (IND) application amendment for the treatment of a biomarker defined patient population of non-small cell lung cancer (NSCLC). The planned phase 1b/2 clinical trial plans to evaluate LP-184... Read More

Webcast to be held Thursday, May 15th, 9:00 a.m. ET, register for the webcast here , or at the link provided below. DALLAS / May 08, 2025 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR ® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it... Read More

The FDA has cleared the investigational new drug (IND) application of LP-184 in triple negative breast cancer (TNBC) treatment – a novel small molecule advanced and developed with Lantern’s AI platform, RADR ® The phase 1b/2 clinical trial plans to evaluate LP-184 in recurrent TNBC patients as both monotherapy and in combination with olaparib. This achievement follows the FDA’s Orphan Drug Designation for LP-184 in TNBC in... Read More

HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024... Read More

Webcast to be held Thursday, March 27th, 4:30 p.m. ET, register for the webcast here , or at the link provided below. DALLAS / Mar 20, 2025 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR ® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it... Read More

DALLAS / Feb 19, 2025 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN) , an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced the publication of its PCT patent application (PCT/US2024/019851) covering a novel machine learning solution for predicting blood-brain barrier (BBB) permeability.... Read More

DALLAS / Jan 27, 2025 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced advancements in the application of its RADR ® AI platform to accelerate and optimize the development of antibody-drug conjugates (ADCs). The global ADC market is... Read More

Multiple clinical trial sites across Taiwan are actively screening patients, following successful site initiation visits. Expansion into Taiwan is particularly significant as over 50% of lung cancer cases in Taiwan occur in never-smokers. DALLAS / Dec 09, 2024 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI... Read More

This is the second Fast Track Designation granted to LP-184 in 2024, following the designation for Glioblastoma (GBM) announced in October 2024. Fast Track Designation for LP-184 recognizes TNBC as a serious condition impacting approximately 29,000 patients annually in the US, with over 50% of patients relapsing within 3-5... Read More

Ten clinical trial sites across Japan and Taiwan are actively screening patients, with additional sites expected to also begin patient enrollment in the coming months U.S. clinical sites continue to actively screen and dose patients in both the LP-300 combination arm and the standard-of-care control arm of the Harmonic trial Non-small cell lung cancer (NSCLC) in never smokers occurs at rates 2 to 3 times higher in East Asian... Read More

Lantern is advancing three AI-guided precision-oncology drug candidates in active Phase 1 and Phase 2 clinical trials, while evaluating additional ADC-based preclinical molecules for development. Preliminary patient data and clinical readouts for the Phase 2 LP-300 Harmonic™ Trial showed an 86% clinical benefit rate in the initial 7 patient lead-in cohort, and additional patients continue to be enrolled in the US. The... Read More

DALLAS / Nov 05, 2024 / Business Wire / Starlight Therapeutics , a wholly-owned subsidiary of Lantern Pharmaceuticals (NASDAQ: LTRN), formed to develop transformative CNS cancer treatments with AI-powered innovation, announced today the formation of a Scientific Advisory Board (“SAB”) to support the development of lead compound STAR-001. The inaugural SAB will work closely with Starlight’s management team to provide... Read More

Webcast to be held Thursday, November 7th, 4:30 p.m. ET, register for the webcast here , or at the link provided below. DALLAS / Oct 31, 2024 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR ® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that... Read More

DALLAS / Oct 23, 2024 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern management will be presenting at the ThinkEquity Conference on Wednesday, October 30, 2024, at 10:30 a.m. ET at the Mandarin Oriental in New York, NY.... Read More

Both webinars will highlight how RADR ® , Lantern’s AI platform, has been used to advance their portfolio and the portfolio of their collaborators. On October 28 th , Lantern’s CEO Panna Sharma will participate in Tribe Public’s webinar event “Leveraging Artificial Intelligence to Develop Therapies for Brain and Childhood Cancers” . On October 30 th , Lantern will host “ Webinar Wednesday ” featuring Andrew Mazar, Ph.D., COO... Read More

Fast Track Designation is designed to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need. Fast Track Designation for LP-184 (STAR-001) recognizes Glioblastoma (GBM) as a serious condition impacting more than 13,000 U.S. adults each year and approximately 300,000 globally. A phase 1b/2a clinical trial for recurrent GBM is targeted to start in late 2024/early 2025. LP-184,... Read More

Lantern Pharma was granted the rare pediatric disease designation (RPDD) for drug-candidate, LP-184, in three cancer indications: Malignant Rhabdoid Tumors, Rhabdomyosarcoma, and Hepatoblastoma. This brings the total number of RPDDs for LP-184 to 4, including one previously granted for ATRT (Atypical Teratoid Rhabdoid Tumors). Efficacy of LP-184 in these three rare pediatric cancers was demonstrated through evidence of tumor... Read More

Active clinical trials across three AI-guided drug candidates with additional ADC-based preclinical molecules in evaluation for development. Preliminary patient data and clinical readouts for Phase 2 LP-300 Harmonic™ Trial released showing an 86% clinical benefit rate in the initial 7 patient safety lead-in cohort. Issued a Certificate of Patent by the Japanese Patent Office directed to Lantern Pharma’s drug candidate... Read More

DALLAS / Aug 07, 2024 / Business Wire / Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement demonstrating the preclinical synergy of LP-184 with checkpoint inhibitors and the ability of LP-184 to resensitize tumors... Read More

The Phase 2 HARMONIC™ study is designed for never smokers with lung adenocarcinoma with the objective to overcome driver mutation(s) – which are more common in never smokers – that lead to tyrosine kinase inhibitor (TKI) treatment resistance, and to enhance patient outcomes when LP-300 is used with the standard-of-care... Read More

Webcast to be held Thursday, August 8th, 4:30 p.m. ET, register for the webcast here , or at the link provided below. DALLAS / Aug 01, 2024 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR ® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it... Read More

DALLAS / Jul 10, 2024 / Business Wire / Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement towards the development... Read More

LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brought to clinical trials by Lantern Pharma using insights and support from RADR ® , Lantern’s AI, machine learning and computational biology platform focused on... Read More

Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% of all lung cancer cases occur in never-smokers with NSCLC; Harmonic™ continues patient enrollment in the US. Phase 1 clinical trials for both... Read More

XCE853 is Oregon Therapeutic’s first-in-class, and potentially best-in-class PDI inhibitor, exhibiting potent preclinical efficacy across multiple solid and hematological cancers, and is ready to advance to Investigational New Drug (IND)-enabling development. The AI-enabled collaboration aims to refine and expand the positioning of XCE853, a novel protein disulfide isomerase (PDI) inhibitor, in new and targeted oncology... Read More

Q1 2024 Earnings Results & Corporate Updates Webcast to be held Thursday, May 9th, 4:30 p.m. ET, register for webcast here , or at the link provided below. DALLAS / May 02, 2024 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR ® AI and machine learning (“ML”) platform with multiple clinical stage... Read More

Webinar Wednesdays is planned to be held on the last Wednesday of each month - starting on Wednesday, April 24th (at 1PM Eastern) with the first webinar on the increasing prevalence of non-small cell lung cancer in never smokers and how drug candidate LP-300 and the Harmonic Clinical Trial is looking to change these outcomes. The second Webinar Wednesdays will focus on drug development needs in an area of critical patient... Read More

Approximately 33% of all non-small cell lung cancer patients in East Asia are never smokers – a growing and unaddressed patient population. Dr. Yashushi Goto a leading lung cancer clinician-scientist at the renowned National Cancer Center of Japan will be a lead investigator. DALLAS / Apr 22, 2024 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and... Read More

Multiple clinical trials across three AI-guided drug candidates are active with first expected data and readouts for LP-184 in the second half of 2024; with additional next-generation drug development programs approaching IND studies. Dosed initial patients in both Phase 1 clinical trials for synthetic lethal drug-candidates, LP-184 and LP-284, each of which are first-in-human molecules with the potential for use across... Read More

LP-284 is in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and other solid tumors. LP-284 is the second of Lantern’s synthetic-lethal franchise of molecules that have been shown to be synthetically lethal in DNA damage repair deficient cancers and has entered into first-in-human clinical trials.... Read More

Webcast to be held Monday, March 18th, 4:30 p.m. ET, register for the webcast here , or at the link provided below. DALLAS / Mar 11, 2024 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR ® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it... Read More

Lantern Pharma will present virtually on Thursday, March 7 th at 2 pm Eastern. Lantern’s CEO & President, Mr. Panna Sharma will be interviewed in the form of a fireside chat by HCW’s Healthcare & Life Sciences Analyst and Director of Equity Research Institutional investors, companies, and industry professionals are encouraged to register at this link or contact their representative at HCW. DALLAS / Mar 05, 2024 / Business... Read More

The rapid growth of Lantern Pharma’s AI platform could lead to accelerated development of better treatments, greater precision in clinical development, and improved combination regimens with the potential for longer and more durable patient responses. Lantern's RADR ® platform recently surpassed 60 billion data points and is planned to exceed 100 billion data points during 2024 and has been crucial in the expansion of the... Read More

Lantern, in collaboration with academic research partners, has advanced the development, synthesis, and preclinical proof-of-concept of a novel, highly potent, cryptophycin-based ADC. The cryptophycin ADC has shown picomolar potency in a wide range of solid tumors tested in preclinical development and is being further... Read More

DALLAS / Jan 17, 2024 / Business Wire / Starlight Therapeutics— a Lantern Pharma (Nasdaq: LTRN) subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options— today announced that Marc Chamberlain, M.D. has joined Starlight as its Chief Medical Officer. Dr. Chamberlain will oversee Starlight’s clinical operations, which... Read More

The Orphan Drug Designation strengthens LP-284’s clinical development path and can provide for additional market exclusivity and commercial protection. Lantern has initiated a first-in-human Phase 1 trial (NCT06132503) for LP-284 in B-cell non-Hodgkin’s lymphomas (NHL), including high-grade B-cell lymphoma (HGBL) and mantle cell lymphoma (MCL). This Orphan Drug Designation marks the second such designation for drug-candidate... Read More

Received IND clearance from FDA to initiate Phase 1 clinical trial for LP-284, a first-in-human trial for advanced, refractory non-Hodgkin’s lymphomas (NHL). Dosed initial patient in Phase 1 with LP-184, a clinical trial for multiple advanced solid tumors that are refractory to standard-of-care therapies. Progressed Phase 2 LP-300 Harmonic™ clinical trial towards enrollment in East Asian countries where 30-35+% of all lung... Read More

Webcast to be held Wednesday, November 8th, 4:30 p.m. ET, register for the webcast here , or at the link provided below. DALLAS / Nov 01, 2023 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR ® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that... Read More

DALLAS / Oct 10, 2023 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR ® , with multiple clinical stage drug programs, today announced that Lantern management will be presenting at the ThinkEquity Conference on Thursday, October 19, 2023, at the Mandarin... Read More

DALLAS / Oct 03, 2023 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR ® , with multiple clinical stage drug programs, today announced that in vivo data highlighting the enhanced efficacy of Lantern’s drug candidate LP-184 in glioblastoma (GBM) were published... Read More

LP-184 is being studied in a first-in-human Phase 1 clinical trial, having been developed with guidance from Lantern’s AI Platform, RADR ® , as a potential therapy for a wide range of advanced solid tumors. LP-184 is one of two molecules in Lantern’s synthetic-lethal franchise that has been shown to have anti-cancer activity in tumors with DNA damage repair deficiency. Lantern estimates that LP-184 has a global aggregate... Read More

This is the second IND Clearance over the last 100 days for drug candidates that are being developed using guidance from Lantern’s AI Platform, RADR ® . LP-284 is the second of Lantern’s synthetic-lethal franchise of molecules that have shown to be synthetically lethal in DNA damage repair deficient cancers and are entering into first-in-human clinical trials. Lantern estimates that LP-284 can have the potential to improve... Read More

DALLAS / Aug 31, 2023 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR ® , with multiple clinical stage drug programs, today announced that it will present positive data highlighting the anti-tumor potency of its drug candidate LP-284 for non-Hodgkin’s lymphoma... Read More

Expansion of RADR ® platform adds new AI capabilities for the automated identification of new and effective combination therapy regimens for immune checkpoint inhibitors (ICI) Additional functionality includes the creation and testing of molecular signatures of ICI response and resistance with a highly scalable, machine-learning based system designed to improve ICI clinical trial outcomes Worldwide, ICIs generated $41.5... Read More

LP-184 is the first of Lantern’s drug candidates developed by leveraging Lantern’s AI platform, RADR ® US FDA previously granted LP-184 Rare Pediatric Disease Designation and Orphan Drug Designation (ODD) for the treatment of pediatric patients with ATRT DALLAS / Aug 14, 2023 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies... Read More

Obtained FDA clearance of the IND application for LP-184 and activated initial clinical sites for the Phase 1 basket trial in relapsed/refractory advanced solid tumors and brain cancers - a patient population with unmet clinical needs. Completed IND-enabling studies for LP-284 and anticipate IND submission in August; first-in-human Phase 1 clinical trial targeted for Q4 in advanced non-Hodgkin’s lymphomas. Dosed initial... Read More

Webcast to be held Wednesday, August 9, 4:30 p.m. ET, register here , or at the link below. DALLAS / Aug 02, 2023 / Business Wire / Lantern Pharma Inc . (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR ® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its second... Read More

DALLAS / Jul 17, 2023 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR ® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that the Company will participate and present at four upcoming conferences: Biotech CEO Summit USA in La Jolla, CA from July... Read More

Non-Hodgkin’s lymphoma (NHL) is the seventh leading cause of cancer in the US, with 20-40% of patients experiencing relapsed or refractory disease with limited or no therapeutic options. Publication highlights in vitro and in vivo results supporting LP-284’s development for mantle cell lymphoma (MCL), an aggressive form of... Read More

LP-184 is a novel, synthetically-lethal, small molecule that has been developed using insights from Lantern’s AI platform, RADR ® . The first-in-human Phase 1A clinical trial has been cleared to proceed by the FDA and is anticipated to launch this summer for multiple advanced solid tumors and brain and central nervous system (CNS) cancers. Lantern has been granted multiple Orphan Drug Designations by the FDA for LP-184 in... Read More

Lantern will leverage its proprietary AI platform, RADR ® , to rapidly develop novel cryptophycin-antibody drug conjugates (ADCs), which represent an exciting class of potent and highly targeted drug candidates. The collaboration with Bielefeld University (Germany) will be led by Professor Norbert Sewald, Ph.D., a leading... Read More

DALLAS / May 17, 2023 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Panna Sharma, CEO and President, will present at the Lytham Partners Spring 2023 Investor Conference on... Read More

Dosed first patient in the Phase 2 Harmonic™ clinical trial; a study for the unique population of non-small lung cancer patients who are never-smokers and who make up 15-20% of all lung cancer cases. Submission of the IND application for LP-184 to the US Food and Drug Administration (FDA) is anticipated this week; a first-in-human Phase 1 clinical trial for LP-184, in genomically defined solid tumors, is targeted to launch... Read More

BELTSVILLE, Md. , May 3, 2023 /CNW/ -- Reprocell USA , a CRO, has been awarded a contract to provide support for Lantern Pharma's Phase 2 clinical trial entitled " A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma (HARMONIC) ". The Harmonic™ study is being conducted to determine clinical advantages for Lantern Pharma's investigational new drug LP-300 in combination with... Read More

Webcast to be held Tuesday, May 9, 4:30 p.m. ET, register here , or at the link below. DALLAS / May 02, 2023 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host its first... Read More

The Blood-Brain-Barrier (BBB) prevents 98% of drugs from entering the brain and is a major limiting factor in the development of brain and central nervous system (CNS) drugs. Lantern’s AI algorithms for predicting BBB permeability have 89-92% accuracy, have been optimized to rapidly generate predictions in around one minute, and are highly scalable to screen thousands of compounds simultaneously. The Therapeutic Data... Read More

DALLAS / Apr 13, 2023 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for U.S. patent... Read More

DALLAS / Mar 28, 2023 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced the dosing of the first patient in the Phase 2 Harmonic™ clinical trial evaluating Lantern’s investigational... Read More

DALLAS / Mar 21, 2023 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern management and employees will be presenting at three upcoming events: Rare Disease Innovation &... Read More

DALLAS / Mar 20, 2023 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the fourth quarter and fiscal year ended December 31, 2022.... Read More

DALLAS / Mar 15, 2023 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the Company will present at the American Association for Cancer Research (AACR) Annual Meeting. Details... Read More

DALLAS / Mar 13, 2023 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host its fourth quarter and fiscal year 2022 financial results webcast on Monday, March 20, 2023 at... Read More

DALLAS / Mar 13, 2023 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that neither Lantern Pharma Inc. nor any of its subsidiaries had any exposure to Silicon Valley Bank (SVB),... Read More

DALLAS / Mar 08, 2023 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host a virtual key opinion leader (KOL) webinar on March 21, 2023 at 12:00 p.m. ET focusing on... Read More

DALLAS / Feb 15, 2023 / Business Wire / Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced expansions and updates to RADR ® ’s product roadmap, which will further enhance its oncology drug discovery... Read More

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it has received guidance from the United States Food and Drug Administration (FDA) on Lantern’s clinical development plans for its LP-184 program.... Read More

The Orphan Drug Designation strengthens LP-284’s clinical development path and provides the opportunity for additional market exclusivity and commercial protection. Lantern is anticipating filing the IND with the FDA and initiating a first-in-human Phase 1 trial for LP-284 in B-cell non-Hodgkin’s lymphomas (NHL), including mantle cell lymphoma (MCL), by mid 2023. In the US, MCL is diagnosed in approximately 4,500 patients... Read More

New data from in vitro, in vivo, and IND enabling studies supports LP-284’s development for MCL, an aggressive form of B-cell non-Hodgkin's lymphoma (NHL) with immediate patient needs. Lantern is anticipating filing the IND with the FDA in early 2023 and initiating a first-in-human Phase 1 trial for LP-284 in NHLs, including... Read More

New preclinical results presented at SABCS demonstrate LP-184 has superior anti-tumor efficacy for TNBC, as compared to current TNBC standard of care agents. LP-184 has therapeutic potential not only for primary TNBCs, but also for brain metastases (mets.) stemming from primary TNBC tumors. Each year in the US, there are approximately 8,000 newly diagnosed TNBC patients with an additional 21,000 relapsed TNBC patients,... Read More